Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBP selective degrader (Aurigene)
- Development stage
- Preclinical
- Lead developer
- Aurigene Oncology
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
This preclinical-stage small molecule is a selective degrader of CREB-binding protein (CBP), developed by Aurigene Discovery Technologies (a subsidiary of Dr. Reddy's Laboratories). Utilizing a Proteolysis-Targeting Chimera (PROTAC) mechanism, the drug selectively targets CBP for proteasomal degradation while sparing its closely related paralog, p300. The therapeutic strategy is based on synthetic lethality: in cancers where the p300 protein (encoded by EP300) is lost or mutated, the tumor cells become uniquely dependent on CBP for transcriptional regulation and survival. By degrading CBP, the molecule induces apoptosis specifically in p300-deficient cancer cells, potentially offering a targeted treatment for various p300-mutant malignancies.
- Other names
- CREB-binding protein selective degraderCBP selective PROTAC
02
Targets
CREBBP (CREB-binding protein)CRBN (Cereblon)
Beyond the preview
Go deeper on CBP selective degrader (Aurigene).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBP selective degrader (Aurigene).